Cargando…
Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results?
OBJECTIVE: Photodynamic diagnosis (PDD) of superficial bladder cancer decreases recurrence rates. We present oncological results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white light (WL) with PDD. The follow-up period is the longest rep...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872595/ https://www.ncbi.nlm.nih.gov/pubmed/20689609 |
_version_ | 1782181236328890368 |
---|---|
author | Otto, Wolfgang Burger, Maximilian Fritsche, Hans-Martin Blana, Andreas Roessler, Wolfgang Knuechel, Ruth Wieland, Wolf F. Denzinger, Stefan |
author_facet | Otto, Wolfgang Burger, Maximilian Fritsche, Hans-Martin Blana, Andreas Roessler, Wolfgang Knuechel, Ruth Wieland, Wolf F. Denzinger, Stefan |
author_sort | Otto, Wolfgang |
collection | PubMed |
description | OBJECTIVE: Photodynamic diagnosis (PDD) of superficial bladder cancer decreases recurrence rates. We present oncological results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white light (WL) with PDD. The follow-up period is the longest reported to date. As costs might be reimbursed by prolonged recurrence-free survival in certain patients cost analysis in regard to risk-groups was performed. MATERIAL AND METHODS: Using chi-square test and log-rank test we compared recurrence rates of 103 patients after WL-TUR and of 88 patients after PDD-TUR. Cost analysis was performed according to risk-groups of recurrence. RESULTS: Mean follow-up was 99 months. Recurrence rate was 57% in WL vs. 28% in PDD (p < 0.001). Costs incurred by subsequent TUR averaged € 2310 per WL patient vs. € 713 per PDD patient. Savings per patient by PDD amounted to € 1597. PDD costs were reimbursed in low, intermediate and high risk patients, respectively. CONCLUSIONS: PDD-TUR is significantly superior to conventional WL-TUR in terms of recurrence rate. While economic benefit is most prominent in intermediate risk patients, PDD related costs are reimbursed in all risk-groups. |
format | Text |
id | pubmed-2872595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-28725952010-05-27 Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results? Otto, Wolfgang Burger, Maximilian Fritsche, Hans-Martin Blana, Andreas Roessler, Wolfgang Knuechel, Ruth Wieland, Wolf F. Denzinger, Stefan Clin Med Oncol Original Research OBJECTIVE: Photodynamic diagnosis (PDD) of superficial bladder cancer decreases recurrence rates. We present oncological results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white light (WL) with PDD. The follow-up period is the longest reported to date. As costs might be reimbursed by prolonged recurrence-free survival in certain patients cost analysis in regard to risk-groups was performed. MATERIAL AND METHODS: Using chi-square test and log-rank test we compared recurrence rates of 103 patients after WL-TUR and of 88 patients after PDD-TUR. Cost analysis was performed according to risk-groups of recurrence. RESULTS: Mean follow-up was 99 months. Recurrence rate was 57% in WL vs. 28% in PDD (p < 0.001). Costs incurred by subsequent TUR averaged € 2310 per WL patient vs. € 713 per PDD patient. Savings per patient by PDD amounted to € 1597. PDD costs were reimbursed in low, intermediate and high risk patients, respectively. CONCLUSIONS: PDD-TUR is significantly superior to conventional WL-TUR in terms of recurrence rate. While economic benefit is most prominent in intermediate risk patients, PDD related costs are reimbursed in all risk-groups. Libertas Academica 2009-04-30 /pmc/articles/PMC2872595/ /pubmed/20689609 Text en © 2009 by the authors http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Original Research Otto, Wolfgang Burger, Maximilian Fritsche, Hans-Martin Blana, Andreas Roessler, Wolfgang Knuechel, Ruth Wieland, Wolf F. Denzinger, Stefan Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results? |
title | Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results? |
title_full | Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results? |
title_fullStr | Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results? |
title_full_unstemmed | Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results? |
title_short | Photodynamic Diagnosis For Superficial Bladder Cancer: do All Risk-Groups Profit Equally From Oncological and Economic Long-Term Results? |
title_sort | photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results? |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872595/ https://www.ncbi.nlm.nih.gov/pubmed/20689609 |
work_keys_str_mv | AT ottowolfgang photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults AT burgermaximilian photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults AT fritschehansmartin photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults AT blanaandreas photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults AT roesslerwolfgang photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults AT knuechelruth photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults AT wielandwolff photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults AT denzingerstefan photodynamicdiagnosisforsuperficialbladdercancerdoallriskgroupsprofitequallyfromoncologicalandeconomiclongtermresults |